165 related articles for article (PubMed ID: 22766748)
1. Serum levels of TUBB3 correlate with clinical outcome in Chinese patients with advanced gastric cancer receiving first-line paclitaxel plus capecitabine.
Yu J; Gao J; Lu Z; Li Y; Shen L
Med Oncol; 2012 Dec; 29(5):3029-34. PubMed ID: 22766748
[TBL] [Abstract][Full Text] [Related]
2. Combination of microtubule associated protein-tau and β-tubulin III predicts chemosensitivity of paclitaxel in patients with advanced gastric cancer.
Yu J; Gao J; Lu Z; Gong J; Li Y; Dong B; Li Z; Zhang X; Shen L
Eur J Cancer; 2014 Sep; 50(13):2328-35. PubMed ID: 25016949
[TBL] [Abstract][Full Text] [Related]
3. Thymidine Phosphorylase/β-tubulin III expressions predict the response in Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Gao J; Lu M; Yu JW; Li YY; Shen L
BMC Cancer; 2011 May; 11():177. PubMed ID: 21586171
[TBL] [Abstract][Full Text] [Related]
4. Prognostic value of expression of Kit67, p53, TopoIIa and GSTP1 for curatively resected advanced gastric cancer patients receiving adjuvant paclitaxel plus capecitabine chemotherapy.
Zha Y; Cun Y; Zhang Q; Li Y; Tan J
Hepatogastroenterology; 2012; 59(117):1327-32. PubMed ID: 22534478
[TBL] [Abstract][Full Text] [Related]
5. Class III β-tubulin is a predictive marker for taxane-based chemotherapy in recurrent and metastatic gastric cancer.
Hwang JE; Hong JY; Kim K; Kim SH; Choi WY; Kim MJ; Jung SH; Shim HJ; Bae WK; Hwang EC; Lee KH; Lee JH; Cho SH; Chung IJ
BMC Cancer; 2013 Sep; 13():431. PubMed ID: 24053422
[TBL] [Abstract][Full Text] [Related]
6. High level of serum AMBP is associated with poor response to paclitaxel-capecitabine chemotherapy in advanced gastric cancer patients.
Huang H; Han Y; Gao J; Feng J; Zhu L; Qu L; Shen L; Shou C
Med Oncol; 2013 Dec; 30(4):748. PubMed ID: 24135868
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial.
Lordick F; Kang YK; Chung HC; Salman P; Oh SC; Bodoky G; Kurteva G; Volovat C; Moiseyenko VM; Gorbunova V; Park JO; Sawaki A; Celik I; Götte H; Melezínková H; Moehler M;
Lancet Oncol; 2013 May; 14(6):490-9. PubMed ID: 23594786
[TBL] [Abstract][Full Text] [Related]
8. Polymorphism of TS 3'-UTR predicts survival of Chinese advanced gastric cancer patients receiving first-line capecitabine plus paclitaxel.
Gao J; He Q; Hua D; Mao Y; Li Y; Shen L
Clin Transl Oncol; 2013 Aug; 15(8):619-25. PubMed ID: 23263912
[TBL] [Abstract][Full Text] [Related]
9. Modified docetaxel and cisplatin in combination with capecitabine (DCX) as a first-line treatment in HER2-negative advanced gastric cancer.
Bilici A; Selcukbiricik F; Demir N; Oven Ustaalioglu BB; Dikilitas M; Yildiz O
Asian Pac J Cancer Prev; 2014; 15(20):8661-6. PubMed ID: 25374186
[TBL] [Abstract][Full Text] [Related]
10. Bevacizumab plus capecitabine and cisplatin in Chinese patients with inoperable locally advanced or metastatic gastric or gastroesophageal junction cancer: randomized, double-blind, phase III study (AVATAR study).
Shen L; Li J; Xu J; Pan H; Dai G; Qin S; Wang L; Wang J; Yang Z; Shu Y; Xu R; Chen L; Liu Y; Yu S; Bu L; Piao Y
Gastric Cancer; 2015 Jan; 18(1):168-76. PubMed ID: 24557418
[TBL] [Abstract][Full Text] [Related]
11. Expression of Class III Beta-tubulin Predicts Prognosis in Patients with Cisplatin-resistant Bladder Cancer Receiving Paclitaxel-based Second-line Chemotherapy.
Miyata Y; Matsuo T; Nakamura Y; Yasuda T; Ohba K; Takehara K; Sakai H
Anticancer Res; 2018 Mar; 38(3):1629-1635. PubMed ID: 29491095
[TBL] [Abstract][Full Text] [Related]
12. [Retrospective study on regimens of capecitabine-based chemotherapy in the treatment for advanced gastric cancer].
Zhang J; Xiao Y; Lu M; Li J; Zhang XD; Li Y; Shen L
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):312-5. PubMed ID: 19615292
[TBL] [Abstract][Full Text] [Related]
13. Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial.
Waddell T; Chau I; Cunningham D; Gonzalez D; Okines AF; Okines C; Wotherspoon A; Saffery C; Middleton G; Wadsley J; Ferry D; Mansoor W; Crosby T; Coxon F; Smith D; Waters J; Iveson T; Falk S; Slater S; Peckitt C; Barbachano Y
Lancet Oncol; 2013 May; 14(6):481-9. PubMed ID: 23594787
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of capecitabine as maintenance treatment after first-line chemotherapy using oxaliplatin and capecitabine in advanced gastric adenocarcinoma patients: a prospective observation.
Qiu MZ; Wei XL; Zhang DS; Jin Y; Zhou YX; Wang DS; Ren C; Bai L; Luo HY; Wang ZQ; Wang FH; Li YH; Yang DJ; Xu RH
Tumour Biol; 2014 May; 35(5):4369-75. PubMed ID: 24515655
[TBL] [Abstract][Full Text] [Related]
15. The prognostic significance of the increase in the serum M30 and M65 values after chemotherapy and relationship between these values and clinicopathological factors in patients with advanced gastric cancer.
Bilici A; Ustaalioglu BB; Ercan S; Seker M; Yilmaz BE; Orcun A; Gumus M
Tumour Biol; 2012 Dec; 33(6):2201-8. PubMed ID: 22890829
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of paclitaxel combined with capecitabine as second-line treatment for advanced gastric carcinoma after failure of cisplatin-based regimens.
Baize N; Abakar-Mahamat A; Mounier N; Berthier F; Caroli-Bosc FX
Cancer Chemother Pharmacol; 2009 Aug; 64(3):549-55. PubMed ID: 19123051
[TBL] [Abstract][Full Text] [Related]
17. Association of high TUBB3 with resistance to adjuvant docetaxel-based chemotherapy in gastric cancer: translational study of ITACA-S.
Di Bartolomeo M; Raimondi A; Cecchi F; Catenacci DVT; Schwartz S; Sellappan S; Tian Y; Miceli R; Pellegrinelli A; Giommoni E; Aitini E; Spada F; Rosati G; Marchet A; Pucci F; Zaniboni A; Tamberi S; Pressiani T; Sanna G; Cantore M; Mosconi S; Bolzoni P; Pinto C; Landi L; Soto Parra HJ; Cavanna L; Corallo S; Martinetti A; Hembrough TA; Pietrantonio F
Tumori; 2021 Apr; 107(2):150-159. PubMed ID: 32522106
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of APE1, BRCA1, ERCC1 and TUBB3 expression in patients with advanced non-small cell lung cancer (NSCLC) receiving first-line platinum-paclitaxel chemotherapy.
Li Z; Qing Y; Guan W; Li M; Peng Y; Zhang S; Xiong Y; Wang D
Cancer Chemother Pharmacol; 2014 Oct; 74(4):777-86. PubMed ID: 25107571
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of paclitaxel and capecitabine as a first-line combination chemotherapy for advanced gastric cancer.
Kang HJ; Chang HM; Kim TW; Ryu MH; Sohn HJ; Yook JH; Oh ST; Kim BS; Lee JS; Kang YK
Br J Cancer; 2008 Jan; 98(2):316-22. PubMed ID: 18219288
[TBL] [Abstract][Full Text] [Related]
20. The multicenter, phase II prospective study of paclitaxel plus capecitabine as first-line chemotherapy in advanced gastric carcinoma.
Gong J; Hu B; Zhang X; Zhang F; Zhang J; Xu N; Fan Q; Bai Y; Jiao S; Wang J; Bai C; Zheng L; Shi Y; Liu Y; Liang J; Hu G; Cheng Y; Xu R; Bai Y; Shen L
Oncologist; 2014 Feb; 19(2):173-4. PubMed ID: 24457378
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
